NCT00501826 2026-01-07
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00006020 2015-03-06
S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00003635 2013-07-18
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002970 2013-07-02
506U78 in Treating Patients With Refractory Hematologic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003545 2013-02-05
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005950 2013-01-23
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00005982 2013-01-23
506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00005080 2013-01-16
506U78 in Treating Patients With Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed